Drugs Made In America Acquisition Corp. (DMAAR) Shares Outstanding (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Shares Outstanding (Entity) for 3 consecutive years, with $30.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) fell 8.07% year-over-year to $30.8 million; the trailing twelve-month figure through Jun 2026 stood at $30.8 million (down 8.07% YoY), and the FY2025 full-year result was $31.5 million, up 219.15% from the prior year.
• Shares Outstanding (Entity) eased to $30.8 million in Q2 2026 per DMAAR's latest filing, from $31.5 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $33.5 million in Q2 2025 and bottomed at $9.9 million in Q4 2024.
• Historically, Shares Outstanding (Entity) has averaged $27.3 million across 3 years, with a median of $31.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) jumped 219.15% in 2025, then retreated 8.07% in 2026.
• Over 3 years, Shares Outstanding (Entity) stood at $9.9 million in 2024, then surged by 219.15% to $31.5 million in 2025, then declined by 2.05% to $30.8 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $30.8 million, $31.5 million, and $33.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.